XML 47 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Lynparza | Licenses and Other    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Finite-lived intangible assets $ 1,100,000,000  
Koselugo | Licenses and Other    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Finite-lived intangible assets 48,000,000  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Sales based milestone payments 700,000,000  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Sales based milestone payments 600,000,000  
Eligible future contingent sales-based milestone payments (up to) 2,000,000,000.0  
Regulatory milestone payments   $ 245,000,000
Eligible future contingent regulatory milestone payments (up to) 0  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Koselugo    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Sales based milestone payments $ 100,000,000